Toward clinically applicable biomarkers for asthma: An EAACI position paper
Top Cited Papers
- 6 April 2019
- Vol. 74 (10), 1835-1851
- https://doi.org/10.1111/all.13806
Abstract
Inflammation, structural and functional abnormalities within the airways are key features of asthma. Although these processes are well‐documented, their expression varies across the heterogeneous spectrum of asthma. Type 2 inflammatory responses are characterized by increased levels of eosinophils, FeNO and type 2 cytokines in blood and/or airways. Presently, type 2 asthma is the best‐defined endotype, typically found in patients with allergic asthma, but surprisingly also in non‐allergic patients with (severe) asthma. The etiology of asthma with non‐type 2 inflammation is less clear. During the past decade, targeted therapies, including biologicals and small molecules, have been increasingly integrated into treatment strategies of severe asthma. These treatments block specific inflammatory pathways or single mediators. Single or composite biomarkers help to identify patients who will benefit from these treatments. So far, only a few inflammatory biomarkers have been validated for clinical application. The European Academy of Allergy & Clinical Immunology (EAACI) Task Force on Biomarkers in Asthma was initiated to review different biomarker sampling methods and to investigate clinical applicability of new and existing inflammatory biomarkers (point‐of‐care) to support diagnosis, targeted treatment and monitoring of severe asthma. Subsequently, we discuss existing and novel targeted therapies for asthma as well as applicable biomarkers.Keywords
This publication has 187 references indexed in Scilit:
- Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammationBMC Pulmonary Medicine, 2013
- Pediatric severe asthma is characterized by eosinophilia and remodeling without TH2 cytokinesJournal of Allergy and Clinical Immunology, 2012
- In vivo imaging of the airway wall in asthma: fibered confocal fluorescence microscopy in relation to histology and lung functionRespiratory Research, 2011
- Use of Exhaled Nitric Oxide Measurement to Identify a Reactive, at-Risk Phenotype among Patients with AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research ProgramAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2010
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthmaThorax, 2007
- Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroidsProceedings of the National Academy of Sciences of the United States of America, 2007
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001